• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Poniard Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 - Product Image

Poniard Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1448649
  • December 2010
  • 88 pages
  • Global Markets Direct

Poniard Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Poniard Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Poniard Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Poniard Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, READ MORE >



List of Tables
List of Figures
Poniard Pharmaceuticals, Inc. Snapshot
Poniard Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Poniard Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Poniard Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Poniard Pharmaceuticals, Inc. – Pipeline Products Glance
Poniard Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Poniard Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Poniard Pharmaceuticals, Inc. – Drug Profiles
Picoplatin
Product Description
Mechanism of Action
R&D Progress
Picoplatin
Product Description
Mechanism of Action
R&D Progress
Picoplatin + Docetaxel + Prednisone/Prednisolone
Product Description
Mechanism of Action
R&D Progress
Picoplatin + FOLPI
Product Description
Mechanism of Action
R&D Progress
Picoplatin
Product Description
Mechanism of Action
R&D Progress
Poniard Pharmaceuticals, Inc. – Pipeline Analysis
Poniard Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Poniard Pharmaceuticals, Inc. Pipeline Products By Target
Poniard Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Poniard Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Poniard Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Aug 03, 2010: Poniard Presents Positive Survival Data From Phase II Clinical Study Of Picoplatin In Metastatic Prostate Cancer
Jun 05, 2010: Poniard Announces Final Data From Phase III SPEAR Trial Of Picoplatin In Small Cell Lung Cancer
Jun 03, 2010: Poniard Pharmaceuticals Presents Positive Survival Data From A Phase 2 Clinical Study Of Picoplatin In Metastatic Prostate Cancer
May 10, 2010: Poniard To Present Results From Phase III SPEAR Trial With Picoplatin At ASCO 2010 Annual Meeting
Mar 19, 2010: US Patent and Trademark Office Grants Reissue Patent On Poniard's Picoplatin Composition of Matter
Mar 19, 2010: US Patent and Trademark Office Grants Reissue Patent On Poniard's Picoplatin Composition of Matter
Jan 25, 2010: Poniard Pharmaceuticals Announces Phase II Trial of Picoplatin In Metastatic Colorectal Cancer Meets Primary Endpoint And Study Objectives
Jan 24, 2010: Poniard Pharmaceuticals Announces Phase 2 Trial Results Of Picoplatin For The Treatment Of Metastatic Colorectal Cancer
Jan 07, 2010: Picoplatin Failed To Meet A Key End-Point In Non-Small Cell Lung Cancer Trial
Nov 17, 2009: Poniard Pharmaceuticals Announces Updated Positive Clinical Data From Phase II Trial Of Picoplatin In Colorectal Cancer
Financial Deals Landscape
Poniard Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Poniard Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Poniard Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Poniard Pharmaceuticals, Inc. Detailed Deal Summary
Asset Purchase
Newalta Income Fund Acquires Lead Recycling Operation From Nova
Molecular Insight Acquires Radiopharmaceutical Manufacturing Facility From NeoRx Manufacturing
Molecular Insight Pharmaceuticals Acquires Manufacturing Facility From NeoRx Manufacturing
Newalta Income Fund Acquires Hazardous Waste And Industrial Cleaning Division Of Services Matrec From TransForce
Newalta Income Fund Sells Industrial On-Site Cleaning Services Operation
Newalta Income Fund Acquires Assets From Lojen Industrial Cleaning
Newalta Income Acquires Assets From WasteCo Environmental Services
Newalta Income Acquires Assets Of Scanland's Vacuum Tankers
Newalta Acquires Hazmat Transportation Services And Waste Logistics From ECL Environmental
Newalta Acquires Mohawk Re-Refinery And Collection Network
Newalta Acquires Industrial Wastewater Recovery Facility From Aqua-Pure
Acquisition
Newalta Acquires Matrix Environmental
Newalta Income Acquires Solutions Environnementales MPM
Newalta Acquires Island Waste Management
Newalta Acquires Norama Industries
Newalta Income Fund Acquires Treeline Environmental Projects And Treeline Well Abandonment and Reclamation
Newalta Income Fund Acquires PSC Industrial Services Canada From Philip Services
Newalta Acquires Anadime
Equity Offering
Poniard Pharmaceuticals Completes Private Placement Of $6.5 Million
Poniard Pharmaceuticals Completes Private Placement Of $7.4 Million
Newalta Completes Offering Of Common Stock For $43 Million
Poniard Pharmaceuticals Completes Public Offering Of $75 Million
Newalta Income Fund Completes $66.68 Million Bought Deal Equity Financing
Newalta Income Fund Closes $169.65 Million Bought Deal Equity Financing
Newalta Income Fund Completes Equity Issue Of $33.7 Million
Newalta Completes Public Offering Of $18.79 Million
Debt Offering
Newalta Income Fund Issues $103.2 Million Convertible Unsecured Debentures
Poniard Pharmaceuticals Extends Research Agreement With The Scripps Research Institute
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS